Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Winfried Rothermel / AP
An FDA panel has recommended that a revolutionary gene therapy treatment — CTL109 from Novartis and the University of Pennsylvania — be approved to fight a rare form of childhood leukemia, which would make it the first gene therapy treatment to reach the market, per the NYT.
Why it matters: It's a potentially game-changing step for cancer treatment. The traditional use of chemotherapy, essentially strong poison sent directly into the bloodstream, might become a thing of the past should gene therapy be proven effective.
- How it works: Millions of a patient's T-cells are removed and reengineered using a disabled form of HIV to become equipped to attack and destroy B-cells, which are a normal part of the immune system but become malignant when a patient has leukemia. The new T-cells are reintroduced to the patient's bloodstream where they become cancer "serial killers."
- The limitations: The time needed to reengineer the cells has been knocked down to 22 days from 4 months, but the treatment can only be performed at 30 to 35 approved medical centers. Plus, the initial side effects can be extremely harsh — with severe reactions — and longer-term side effects might still pop up.